Deoxyribonucleic Acid (DNA) Manufacturing Market Report 2026

The deoxyribonucleic acid (dna) manufacturing market size has grown rapidly in recent years. It will grow from $5.58 billion in 2025 to $6.51 billion in 2026 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to limited access to high-quality plasmid and synthetic dna, reliance on traditional chemical dna synthesis methods, growing r&d in cell and gene therapies, rising academic and industrial research initiatives, increasing demand for oligonucleotide-based drugs.

The deoxyribonucleic acid (dna) manufacturing market size is expected to see rapid growth in the next few years. It will grow to $11.95 billion in 2030 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to advancements in enzymatic and chemical dna synthesis technologies, expansion of gene therapy and vaccine pipelines, increasing adoption of gmp-grade dna production, rising demand for long and complex dna constructs, integration of automated dna manufacturing platforms and digital workflows. Major trends in the forecast period include rising demand for gmp-grade dna for therapeutic applications, growth in plasmid and synthetic dna production for vaccines, increasing adoption of gene synthesis and codon optimization services, expansion of oligonucleotide synthesis for pcr, sirna, and antisense applications, integration of dna manufacturing in cell and gene therapy pipelines.

Increasing demand for gene therapies is expected to propel the growth of the deoxyribonucleic acid (DNA) manufacturing market going forward. Gene therapies refer to techniques that modify or replace faulty genes to treat or prevent diseases, while personalized medicine refers to tailoring medical treatment to an individual’s genetic, biological, and lifestyle characteristics. The increasing demand for gene therapies is driven by the rising prevalence of genetic disorders such as cystic fibrosis, sickle cell anemia, and certain types of inherited blindness. Deoxyribonucleic acid (DNA) manufacturing supports gene therapies by providing the high-quality, custom DNA sequences necessary to develop and deliver therapeutic genes that can correct or replace faulty genetic material in patients. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization, in fourth quarter of 2024, the number of pre-registration gene therapy programs experienced its largest increase in over a year, rising 83% compared to third quarter of 2024. Therefore, the increasing demand for gene therapies is driving the growth of the deoxyribonucleic acid (DNA) manufacturing market.

Major companies operating in the DNA manufacturing market are focusing on developing innovative approaches, such as GMP-grade plasmid DNA production, to enhance the quality, safety, and scalability of gene and cell therapy applications. GMP-grade plasmid DNA production refers to the manufacture of plasmid DNA under Good Manufacturing Practice (GMP) conditions, which are regulatory guidelines ensuring the quality, safety, and consistency of biopharmaceutical products. For instance, in April 2025, ProBio Genomics Inc., a US-based contract development and manufacturing organization (CDMO), launched GMP Plasmid DNA Manufacturing Services in Hopewell with in-house analytical testing, method development, and project management. It offers unique features, including in-house process development, analytical testing, method development, and project management, eliminating the need for multiple suppliers and speeding up development timelines. The service ensures high-quality output with ≥85% supercoiled plasmid DNA content while minimizing contamination risks. ProBio also offers GMP-like plasmids with a four-week delivery timeline and full GMP-grade plasmids within three months.

In February 2025, Maravai LifeSciences Holdings, Inc., a U.S.-based life sciences company, acquired Officinae Bio S.r.l. for an undisclosed amount. With this acquisition, Maravai aims to integrate Officinae’s AI-enabled mRNA and DNA sequence design platform into its TriLink nucleic acid production business, accelerating the development of next-generation nucleic acid therapies. Officinae Bio S.r.l. is an Italy based biotech company specializing in AI-driven digital platforms for the biological design of DNA and RNA therapeutics.

Major companies operating in the deoxyribonucleic acid (dna) manufacturing market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, Kaneka Corporation, Catalent Inc., Charles River Laboratories International Inc., WuXi Biologics Inc., AGC Biologics Inc., Integrated DNA Technologies Inc., GenScript Biotech Corporation, Takara Bio USA Inc., Twist Bioscience Corp., Ajinomoto Bio-Pharma Services, OriGene Technologies Inc., DNA Script SAS, Eurofins Genomics LLC, Touchlight Genetics Ltd., Elegen Inc., VGXI Inc., PlasmidFactory GmbH & Co. KG.

North America was the largest region in the deoxyribonucleic acid (DNA) manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the deoxyribonucleic acid (dna) manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the deoxyribonucleic acid (dna) manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the DNA manufacturing market by increasing the cost of imported enzymes, nucleotides, reagents, and specialized synthesis equipment. Segments like plasmid DNA, synthetic DNA, and oligonucleotide synthesis are particularly affected, with Asia-Pacific regions including China and India being major exporters of raw materials and instruments. This has led to higher production costs and potential delays in supply. On the positive side, tariffs have encouraged local manufacturing, investment in domestic production facilities, and innovation in cost-effective DNA synthesis technologies.

The deoxyribonucleic acid (dna) manufacturing market research report is one of a series of new reports that provides deoxyribonucleic acid (dna) manufacturing market statistics, including deoxyribonucleic acid (dna) manufacturing industry global market size, regional shares, competitors with a deoxyribonucleic acid (dna) manufacturing market share, detailed deoxyribonucleic acid (dna) manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the deoxyribonucleic acid (dna) manufacturing industry. This deoxyribonucleic acid (dna) manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Deoxyribonucleic acid (DNA) manufacturing refers to the process of artificially creating or replicating deoxyribonucleic acid (DNA) sequences using advanced biochemical techniques. This involves synthesizing specific nucleotide sequences or amplifying existing DNA strands to produce large quantities of genetic material with high accuracy and purity.

The main types of deoxyribonucleic acid (DNA) manufacturing are plasmid deoxyribonucleic acid (DNA), synthetic deoxyribonucleic acid (DNA), gene synthesis, and oligonucleotide synthesis. Plasmid deoxyribonucleic acid (DNA) refers to a small, circular, double-stranded DNA molecule that exists independently of the chromosomal DNA within a cell. The multiple grades involved include good manufacturing practices (GMP) grade and research and development grade through various distribution applications such as cell and gene therapy, vaccines, oligonucleotide-based drugs, and others and cater to several end users such as pharmaceutical and biotechnology companies, academic and research institutes, and contract research organizations.

The deoxyribonucleic acid (DNA) manufacturing market consists of sales of synthetic DNA, plasmid DNA, linear DNA, oligonucleotides, and gene constructs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.